Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RCKT with free AI briefings, catalyst countdowns, and dilution alerts.

RCKT · Rocket Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$269.5M Cash on Hand
20.6mo Cash Runway
Follow RCKT by email Get an email when RCKT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RCKT, unsubscribe in one click. Privacy

📣 What RCKT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Xuebijing Pulmonary Disease, Chronic Obstructive Phase 4 · NCT02937974 Unknown
Mozafancogene Autotemcel Fanconi Anemia Complementation Group A Phase 2 · NCT04248439 Active not recruiting
RP-L201 Leukocyte Adhesion Defect - Type I Phase 1/2 · NCT03812263 Completed
RP-L301 Pyruvate Kinase Deficiency Phase 2 · NCT06422351 Suspended
Genetically Engineered Hematopoietic Stem… Fanconi Anemia Phase 1 · NCT01331018 Terminated
Methylprednisolone Fanconi Anemia Phase 1 · NCT01331018 Terminated
RP-A501 Danon Disease Phase 1 · NCT03882437 Completed
Autologous CD34+-enriched HSPCs Transduced with… Infantile Malignant Osteopetrosis Phase 1 · NCT04525352 Terminated

Also used in these trials (approved or third-party drugs, not RCKT's own candidates): Filgrastim, Plerixafor, Prednisone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RCKT holds $269.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $39.3M/quarter from operations, an estimated runway of 20.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 13 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RCKT files for a raise →

👥 Who Owns RCKT

Insiders 19.9% Institutions (251 holders) 80.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
Roderick Wong
Director, 10% owner · +78,960 options
Insider 18,263,956 16.36% 2026-06-18
Gaurav Shah
CEO · +870,648 options
Insider 1,462,832 1.31% 2026-08-18
Martin Wilson
General Counsel · +468,187 options
Insider 545,100 0.49% 2026-11-05
Christopher James Stevens
Chief Operating Officer · +194,465 options
Insider 505,784 0.45% 2026-08-11
Syed Ali-aamir Rizvi
Chief Medical Officer · +93,037 options
Insider 407,874 0.37% 2026-02-11
David P Southwell
Director · +64,860 options
Insider 317,646 0.28% 2026-08-03
Sarbani Chaudhuri
Chief Commercial & Medical Affairs Offic · +189,076 options
Insider 257,937 0.23% 2026-11-09
John Militello
Vice President of Finance, Treasurer, Pr · +161,580 options
Insider 89,780 0.08% 2026-05-19
Peter Fong
Director · +64,860 options
Insider 76,195 0.07% 2026-06-18
Mikael Dolsten
Director · +64,860 options
Insider 67,082 0.06% 2026-06-18
Carsten Boess
Director · +64,860 options
Insider 52,862 0.05% 2026-06-18
Fady Ibraham Malik
Director · +64,860 options
Insider 52,862 0.05% 2026-06-18

Share count 111,660,283 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RCKT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RCKT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.